NASD · Healthcare · Diagnostics & Research · USA
Caredx Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
CareDx develops diagnostic testing and digital solutions for transplant patients and centers. The company offers blood-based tests to detect organ rejection in heart, kidney, and lung recipients, along with pre-transplant products and pharmacy services. Operating laboratories in California, Nebraska, and Sweden, CareDx serves transplant facilities across the United States and Europe.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Caredx Inc stock.
Overvalued: intrinsic value $41.64 per share, market price $74.56, margin of safety -79.1% (as of 2026-11-17).
A 4.0x revenue multiple, discounted for its losses, values the shares at $41.64; the price of $74.56 is 79% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
5 more in this industry show a wider margin of safety.
CDNA is overvalued (as of the 2026-11-17 close). A 4.0x revenue multiple, discounted for its losses, values the shares at $41.64; the price of $74.56 is 79% above that value.
$41.64 per share (as of the 2026-11-17 close), against a market price of $74.56. That is a margin of safety of -79.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.